Syros Pharmaceuticals, Inc (NASDAQ:SYRS) Set For Revaluation As WMDST Values Stock Under-Valued
Balance between a large liquidity cushion and negative cash flow creates a near-term tug-of-war; valuation inputs favor upward reassessment while momentum indicators limit immediate upside.







